Tetra Bio-Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Guy Chamberland

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	6.1yrs
CEO ownership	n/a
Management average tenure	3.7yrs
Board average tenure	6.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Guy Chamberland's remuneration changed compared to Tetra Bio-Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Aug 31 2022	n/a	n/a	-CA$39m
May 31 2022	n/a	n/a	-CA$41m
Feb 28 2022	n/a	n/a	-CA$45m
Nov 30 2021	CA$437k	CA$325k	-CA$52m
Aug 31 2021	n/a	n/a	-CA$29m
May 31 2021	n/a	n/a	-CA$28m
Feb 28 2021	n/a	n/a	-CA$25m
Nov 30 2020	CA$472k	CA$298k	-CA$21m
Aug 31 2020	n/a	n/a	-CA$17m
May 31 2020	n/a	n/a	-CA$15m
Feb 29 2020	n/a	n/a	-CA$14m
Nov 30 2019	CA$295k	CA$214k	-CA$13m
Aug 31 2019	n/a	n/a	-CA$14m
May 31 2019	n/a	n/a	-CA$10m
Feb 28 2019	n/a	n/a	-CA$10m
Nov 30 2018	CA$263k	CA$191k	-CA$8m
Aug 31 2018	n/a	n/a	-CA$5m
May 31 2018	n/a	n/a	-CA$8m
Feb 28 2018	n/a	n/a	-CA$7m
Nov 30 2017	CA$153k	CA$153k	-CA$6m

Compensation vs Market: Insufficient data to establish whether Guy's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Guy's compensation with company performance.

CEO

Guy Chamberland (61 yo)

6.1yrs

Tenure

CA$436,642

Compensation

Dr. Guy Chamberland, M.Sc., Ph D., Master Herbalist, has been the Chief Executive Officer and Chief Regulatory Officer at Tetra Bio-Pharma Inc. since October 15, 2018 and serves as its Director since June...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Guy Chamberland	Co-Founder	6.1yrs	CA$436.64k	no data
Steeve Néron	Chief Commercial Officer	3.7yrs	CA$313.61k	no data
André Rancourt	Co-Founder	no data	no data	no data
Leslie Auld	Chief Financial Officer	2yrs	no data	no data
Jennifer McCaughey	Vice President of Investor Relations	no data	no data	no data
Dania Scott	Senior Vice President of Commercial Strategy	3.7yrs	no data	no data
Aurelia Pauw	Senior VP of Clinical Programs & Medical Affairs	3.3yrs	no data	no data
Richard Giguere	Chief Executive Officer of Tetra Natural Health Inc.	5.6yrs	no data	no data
Randy Ringuette	Project Director & Member of Advisory Board	no data	no data	no data
Chris MacLean	Chief Operating Officer of Tetra Natural Health	5yrs	no data	no data

3.7yrs

Average Tenure

Experienced Management: TBPM.Q's management team is considered experienced (3.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Guy Chamberland	Co-Founder	4.9yrs	CA$436.64k	no data
Randy Ringuette	Project Director & Member of Advisory Board	8.5yrs	no data	no data
Catherine Auld	Independent Director	3yrs	CA$56.76k	no data
Steven Edgett	Member of Strategic Advisor	3.8yrs	no data	no data
Brent Norton	Independent Chairman	3.7yrs	CA$151.76k	no data
Adam Greenblatt	Member of Advisory Board	8.5yrs	no data	no data
Erin Prosk	Member of Advisory Board	8.5yrs	no data	no data
Charles Campbell	Member of Advisory Board	8.5yrs	no data	no data
Louis-Philippe de Lorimier	Member of Clinical Advisory Board	6.7yrs	no data	no data
Cheryl Cullen	Member of Clinical Advisory Board	6.6yrs	no data	no data
Aubrey Webb	Member of Clinical Advisory Board	6.6yrs	no data	no data
John Kim	Independent Director	3yrs	CA$56.76k	no data

6.6yrs

Average Tenure

61yo

Average Age

Experienced Board: TBPM.Q's board of directors are considered experienced (6.6 years average tenure).

Tetra Bio-Pharma Management

Management criteria checks 2/4

Key information

Recent management updates

Tetra Bio-Pharma Inc. Appoints Leslie Auld as Chief Financial Officer

Tetra Bio-Pharma Inc., Annual General Meeting, May 28, 2021

Tetra Bio-Pharma Inc. Announces Management Appointments

Recent updates

Tetra Bio-Pharma Inc. Provides Its Shareholders with Another Regulatory Update on the REDUVO™ New Drug Submission

Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir

Tetra Bio-Pharma Inc. Provides Update on Its REDUVO™ New Drug Submission

Tetra Bio-Pharma Inc. and Prepaire Jointly Apply to BARDA for Funding

Tetra Bio-Pharma Inc. announced that it expects to receive CAD 6 million in funding from Alpha Blue Ocean Advisors Ltd

Tetra Bio-Pharma Inc. Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections

Tetra Bio-Pharma Inc. Provides Regulatory Update

Tetra Bio-Pharma Inc. Appoints Leslie Auld as Chief Financial Officer

Tetra Bio-Pharma Receives Ema Orphan Drug Designation for A Novel Topical Therapeutic Containing Cbd

Tetra Bio-Pharma Inc. announced that it expects to receive funding from Cannvalate PTY LTD

Tetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBD

Tetra Bio-Pharma Inc. has completed a Composite Units Offering in the amount of CAD 2.129432 million.

Tetra Bio-Pharma Inc. Announces Positive Initial Clinical Data from its Ongoing Phase 2 Clinical Trials (REBORN©1 and PLENITUDE©) of QIXLEEF™ for Cancer Pain

Tetra Bio-Pharma Accelerates REBORN1© Trial

Significant Discovery Reveals New Antiviral Properties of Tetra Bio- Pharma's Innovative Drug ARDS-003

Health Canada Accepts New Drug Submission for REDUVO™ as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting

Tetra Bio-Pharma Announces Clinical Advancements

Tetra Bio-Pharma Inc. has completed a Composite Units Offering in the amount of CAD 10 million.

Tetra Bio-Pharma Inc. Accelerates Plenitude Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain

Tetra Bio-Pharma Announces Start of the Reborn1(C) Clinical Trial

Tetra Bio-Pharma Inc. Re-Activates Veterinary Clinical Study in Companion Animals

Tetra Bio-Pharma Inc., Annual General Meeting, May 28, 2021

Tetra Bio-Pharma Provides Status of its New Drug Submission Application in Canada

Tetra Bio-Pharma Inc. has completed a Composite Units Offering in the amount of CAD 12.54 million.

Tetra Bio-Pharma Inc. (TSX:TBP) entered into a non-binding term sheet to acquire remaining 80% stake in Targeted Pharmaceuticals, LLC for approximately $9.5 million.

Tetra Bio-Pharma Inc. announced that it has received CAD 1.884461 million in funding

Tetra Bio-Pharma Announces FDA Clearance on IND, Allowing U.S. Reborn Clinical Trial to Commence

Tetra Bio-Pharma Inc. announced that it expects to receive CAD 1.894 million in funding

Tetra Bio-Pharma Inc. Completes Investigational New Drug (Ind) -Enabling Toxicology, Clearing the Way for Human Clinical Trials for Its Novel Drug Candidate Ards-003

Tetra Bio-Pharma Inc. Provides Update on Market Potential of ARDS-003

Mondias Natural Products Inc. (TSXV:NHP) completed the acquisition of Lumiera Health Innovation Inc. from Tetra Bio-Pharma Inc. (TSXV:TBP) and certain minority shareholders.

Tetra Bio-Pharma Inc. Unveils Its Commercial Vision on a Robust Chemotherapy Induced Nausea and Vomiting Portfolio

Tetra Bio-Pharma Inc. Enters into A Definitive Agreement with a USA Strategic Partner to Acquire the Canadian Exclusive Rights for Dronabinol Soft Gel Capsules

Tetra Bio-Pharma Inc. Announces Management Appointments

Tetra Bio-Pharma Inc.(TSXV:TBP) dropped from S&P/TSX Venture Composite Index

Mondias Natural Products Inc. (TSXV:NHP) signed a binding letter of intent to acquire Lumiera Health Innovation Inc. from Tetra Bio-Pharma Inc. (TSXV:TBP) for CAD 1.4 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age